Athira Pharma, Inc. announced that it will host a webinar event with key opinion leaders to discuss the unmet medical need and the potential opportunity for fosgonimeton to improve cognition and function in mild-to-moderate Alzheimer?s disease. With the Phase 2/3 LIFT-AD study expected to report topline data in the second half of 2024, The company look forward to being joined by two renowned leaders in the neurodegeneration field to discuss the continued need for new treatment options in Alzheimer?s disease. The company will address important aspects of AD pathology relevant to this patient population and will review the potential opportunity for fosgonimeton to improve cognition and function in patients suffering with mild-to-moderate AD.